ADP-induced platelet reactivity and bleeding events in patients with acute myocardial infarction complicated by cardiogenic shock
Platelets. 2021 May 3:1-10. doi: 10.1080/09537104.2021.1913577. Online ahead of print.ABSTRACTWhile previous reports showed ADP-induced platelet reactivity to be an independent predictor of bleeding after PCI in stable patients, this has never been investigated in patients with cardiogenic shock. The association of bleeding events with respect to ADP-induced platelet aggregation was investigated in patients undergoing primary PCI for acute myocardial infarction complicated by cardiogenic shock and with available on-treatment ADP-induced platelet aggregation measurements. Out of 233 patients, 74 suffered from a severe BARC3...
Source: Platelets - May 4, 2021 Category: Hematology Authors: Clemens Scherer Enzo L üsebrink Danny Kupka Thomas J Stocker Konstantin Stark Jan Kleeberger Mathias Orban Antonia Kellnar Tobias Petzold Simon Deseive Kathrin Krieg Sara W ürbel Sara Kika Mario Istrefi Stefan Brunner Daniel Braun Christian Hagl J örg Source Type: research

A double-edged sword: antibody-mediated procoagulant platelets in COVID-19
Platelets. 2021 Apr 23:1-3. doi: 10.1080/09537104.2021.1912315. Online ahead of print.NO ABSTRACTPMID:33890850 | DOI:10.1080/09537104.2021.1912315 (Source: Platelets)
Source: Platelets - April 23, 2021 Category: Hematology Authors: Sarah L Millington-Burgess Matthew T Harper Source Type: research

Why do platelets express K(+) channels?
Platelets. 2021 Apr 19:1-8. doi: 10.1080/09537104.2021.1904135. Online ahead of print.ABSTRACTPotassium ions have widespread roles in cellular homeostasis and activation as a consequence of their large outward concentration gradient across the surface membrane and ability to rapidly move through K+-selective ion channels. In platelets, the predominant K+ channels include the voltage-gated K+ channel Kv1.3, and the intermediate conductance Ca2+-activated K+ channel KCa3.1, also known as the Gardos channel. Inwardly rectifying potassium GIRK channels and KCa1.1 large conductance Ca2+-activated K+ channels have also been repo...
Source: Platelets - April 19, 2021 Category: Hematology Authors: Joy R Wright Martyn P Mahaut-Smith Source Type: research

Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison
Platelets. 2021 Apr 15:1-6. doi: 10.1080/09537104.2021.1904134. Online ahead of print.ABSTRACTDual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is prescribed for 1-year after myocardial infarction. Two clinical strategies are considered at 1-year: continuation of DAPT or "Dual Pathway" (DP), using aspirin and rivaroxaban. No head-to-head comparative studies exist. In our in-vitro study, 24 samples of donor blood were treated with clinically proven concentrations of 5 antithrombotic regimens: aspirin, ticagrelor, rivaroxaban, DAPT, and DP. Thrombosis was analyzed using the Total Thrombus Analysis...
Source: Platelets - April 15, 2021 Category: Hematology Authors: Cole R Clifford Richard G Jung Benjamin Hibbert Aun Yeong Chong Marie Lordkipanidz é Jean-Francois Tanguay Derek Y F So Source Type: research

Not-high before-treatment platelet reactivity in patients with STEMI: prevalence, clinical characteristics, response to therapy and outcomes
Platelets. 2021 Apr 15:1-8. doi: 10.1080/09537104.2021.1915973. Online ahead of print.ABSTRACTPlatelet reactivity (PR) has been indicated as a pathophysiological key element for ST-Elevation Myocardial Infarction (STEMI) development. Patients with not-high before-treatment platelet reactivity (NHPR) have been poorly studied so far. The aim of this study is to investigate the prevalence, clinical characteristics, response to therapy and outcomes of baseline prior to treatment NHPR among patients with STEMI undergoing primary PCI.We analyzed the data from 358 STEMI patients with assessment of PR by VerifyNow before P2Y12 inh...
Source: Platelets - April 15, 2021 Category: Hematology Authors: Mario E Canonico Giuseppe D Sanna Roberta Siciliano Simona Guarino Benedetta Bellandi Fernando Scudiero Pier Sergio Saba Giovanni Esposito Dimitrios Alexopoulos Guido Parodi Source Type: research

Effects of electret coating technology on coronary stent thrombogenicity
Platelets. 2021 Apr 15:1-8. doi: 10.1080/09537104.2021.1912313. Online ahead of print.ABSTRACTStent thrombosis (ST) is a catastrophic event and efforts to reduce its incidence by altering blood-stent interactions are longstanding. A new electret coating technology that produces long-lasting negative charge on stent surface could make them intrinsically resistant to thrombosis. We assessed the thrombogenicity of stents using an annular perfusion model with confocal microscopy, and determined the efficacy of electret coating technology to confer thrombo-resistant properties to standard stents. Using an annular perfusion cham...
Source: Platelets - April 15, 2021 Category: Hematology Authors: M Urooj Zafar Jose Javier Bravo-Cordero Sergi Torramade-Moix Gines Escolar Didac Jerez-Dolz Eli I Lev Juan Jose Badimon Source Type: research

Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison
Platelets. 2021 Apr 15:1-6. doi: 10.1080/09537104.2021.1904134. Online ahead of print.ABSTRACTDual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is prescribed for 1-year after myocardial infarction. Two clinical strategies are considered at 1-year: continuation of DAPT or "Dual Pathway" (DP), using aspirin and rivaroxaban. No head-to-head comparative studies exist. In our in-vitro study, 24 samples of donor blood were treated with clinically proven concentrations of 5 antithrombotic regimens: aspirin, ticagrelor, rivaroxaban, DAPT, and DP. Thrombosis was analyzed using the Total Thrombus Analysis...
Source: Platelets - April 15, 2021 Category: Hematology Authors: Cole R Clifford Richard G Jung Benjamin Hibbert Aun Yeong Chong Marie Lordkipanidz é Jean-Francois Tanguay Derek Y F So Source Type: research

Not-high before-treatment platelet reactivity in patients with STEMI: prevalence, clinical characteristics, response to therapy and outcomes
Platelets. 2021 Apr 15:1-8. doi: 10.1080/09537104.2021.1915973. Online ahead of print.ABSTRACTPlatelet reactivity (PR) has been indicated as a pathophysiological key element for ST-Elevation Myocardial Infarction (STEMI) development. Patients with not-high before-treatment platelet reactivity (NHPR) have been poorly studied so far. The aim of this study is to investigate the prevalence, clinical characteristics, response to therapy and outcomes of baseline prior to treatment NHPR among patients with STEMI undergoing primary PCI.We analyzed the data from 358 STEMI patients with assessment of PR by VerifyNow before P2Y12 inh...
Source: Platelets - April 15, 2021 Category: Hematology Authors: Mario E Canonico Giuseppe D Sanna Roberta Siciliano Simona Guarino Benedetta Bellandi Fernando Scudiero Pier Sergio Saba Giovanni Esposito Dimitrios Alexopoulos Guido Parodi Source Type: research

Effects of electret coating technology on coronary stent thrombogenicity
Platelets. 2021 Apr 15:1-8. doi: 10.1080/09537104.2021.1912313. Online ahead of print.ABSTRACTStent thrombosis (ST) is a catastrophic event and efforts to reduce its incidence by altering blood-stent interactions are longstanding. A new electret coating technology that produces long-lasting negative charge on stent surface could make them intrinsically resistant to thrombosis. We assessed the thrombogenicity of stents using an annular perfusion model with confocal microscopy, and determined the efficacy of electret coating technology to confer thrombo-resistant properties to standard stents. Using an annular perfusion cham...
Source: Platelets - April 15, 2021 Category: Hematology Authors: M Urooj Zafar Jose Javier Bravo-Cordero Sergi Torramade-Moix Gines Escolar Didac Jerez-Dolz Eli I Lev Juan Jose Badimon Source Type: research

Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison
Platelets. 2021 Apr 15:1-6. doi: 10.1080/09537104.2021.1904134. Online ahead of print.ABSTRACTDual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is prescribed for 1-year after myocardial infarction. Two clinical strategies are considered at 1-year: continuation of DAPT or "Dual Pathway" (DP), using aspirin and rivaroxaban. No head-to-head comparative studies exist. In our in-vitro study, 24 samples of donor blood were treated with clinically proven concentrations of 5 antithrombotic regimens: aspirin, ticagrelor, rivaroxaban, DAPT, and DP. Thrombosis was analyzed using the Total Thrombus Analysis...
Source: Platelets - April 15, 2021 Category: Hematology Authors: Cole R Clifford Richard G Jung Benjamin Hibbert Aun Yeong Chong Marie Lordkipanidz é Jean-Francois Tanguay Derek Y F So Source Type: research

Not-high before-treatment platelet reactivity in patients with STEMI: prevalence, clinical characteristics, response to therapy and outcomes
Platelets. 2021 Apr 15:1-8. doi: 10.1080/09537104.2021.1915973. Online ahead of print.ABSTRACTPlatelet reactivity (PR) has been indicated as a pathophysiological key element for ST-Elevation Myocardial Infarction (STEMI) development. Patients with not-high before-treatment platelet reactivity (NHPR) have been poorly studied so far. The aim of this study is to investigate the prevalence, clinical characteristics, response to therapy and outcomes of baseline prior to treatment NHPR among patients with STEMI undergoing primary PCI.We analyzed the data from 358 STEMI patients with assessment of PR by VerifyNow before P2Y12 inh...
Source: Platelets - April 15, 2021 Category: Hematology Authors: Mario E Canonico Giuseppe D Sanna Roberta Siciliano Simona Guarino Benedetta Bellandi Fernando Scudiero Pier Sergio Saba Giovanni Esposito Dimitrios Alexopoulos Guido Parodi Source Type: research

Effects of electret coating technology on coronary stent thrombogenicity
Platelets. 2021 Apr 15:1-8. doi: 10.1080/09537104.2021.1912313. Online ahead of print.ABSTRACTStent thrombosis (ST) is a catastrophic event and efforts to reduce its incidence by altering blood-stent interactions are longstanding. A new electret coating technology that produces long-lasting negative charge on stent surface could make them intrinsically resistant to thrombosis. We assessed the thrombogenicity of stents using an annular perfusion model with confocal microscopy, and determined the efficacy of electret coating technology to confer thrombo-resistant properties to standard stents. Using an annular perfusion cham...
Source: Platelets - April 15, 2021 Category: Hematology Authors: M Urooj Zafar Jose Javier Bravo-Cordero Sergi Torramade-Moix Gines Escolar Didac Jerez-Dolz Eli I Lev Juan Jose Badimon Source Type: research

Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison
Platelets. 2021 Apr 15:1-6. doi: 10.1080/09537104.2021.1904134. Online ahead of print.ABSTRACTDual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is prescribed for 1-year after myocardial infarction. Two clinical strategies are considered at 1-year: continuation of DAPT or "Dual Pathway" (DP), using aspirin and rivaroxaban. No head-to-head comparative studies exist. In our in-vitro study, 24 samples of donor blood were treated with clinically proven concentrations of 5 antithrombotic regimens: aspirin, ticagrelor, rivaroxaban, DAPT, and DP. Thrombosis was analyzed using the Total Thrombus Analysis...
Source: Platelets - April 15, 2021 Category: Hematology Authors: Cole R Clifford Richard G Jung Benjamin Hibbert Aun Yeong Chong Marie Lordkipanidz é Jean-Francois Tanguay Derek Y F So Source Type: research

Not-high before-treatment platelet reactivity in patients with STEMI: prevalence, clinical characteristics, response to therapy and outcomes
Platelets. 2021 Apr 15:1-8. doi: 10.1080/09537104.2021.1915973. Online ahead of print.ABSTRACTPlatelet reactivity (PR) has been indicated as a pathophysiological key element for ST-Elevation Myocardial Infarction (STEMI) development. Patients with not-high before-treatment platelet reactivity (NHPR) have been poorly studied so far. The aim of this study is to investigate the prevalence, clinical characteristics, response to therapy and outcomes of baseline prior to treatment NHPR among patients with STEMI undergoing primary PCI.We analyzed the data from 358 STEMI patients with assessment of PR by VerifyNow before P2Y12 inh...
Source: Platelets - April 15, 2021 Category: Hematology Authors: Mario E Canonico Giuseppe D Sanna Roberta Siciliano Simona Guarino Benedetta Bellandi Fernando Scudiero Pier Sergio Saba Giovanni Esposito Dimitrios Alexopoulos Guido Parodi Source Type: research

Effects of electret coating technology on coronary stent thrombogenicity
Platelets. 2021 Apr 15:1-8. doi: 10.1080/09537104.2021.1912313. Online ahead of print.ABSTRACTStent thrombosis (ST) is a catastrophic event and efforts to reduce its incidence by altering blood-stent interactions are longstanding. A new electret coating technology that produces long-lasting negative charge on stent surface could make them intrinsically resistant to thrombosis. We assessed the thrombogenicity of stents using an annular perfusion model with confocal microscopy, and determined the efficacy of electret coating technology to confer thrombo-resistant properties to standard stents. Using an annular perfusion cham...
Source: Platelets - April 15, 2021 Category: Hematology Authors: M Urooj Zafar Jose Javier Bravo-Cordero Sergi Torramade-Moix Gines Escolar Didac Jerez-Dolz Eli I Lev Juan Jose Badimon Source Type: research

Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison
Platelets. 2021 Apr 15:1-6. doi: 10.1080/09537104.2021.1904134. Online ahead of print.ABSTRACTDual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is prescribed for 1-year after myocardial infarction. Two clinical strategies are considered at 1-year: continuation of DAPT or "Dual Pathway" (DP), using aspirin and rivaroxaban. No head-to-head comparative studies exist. In our in-vitro study, 24 samples of donor blood were treated with clinically proven concentrations of 5 antithrombotic regimens: aspirin, ticagrelor, rivaroxaban, DAPT, and DP. Thrombosis was analyzed using the Total Thrombus Analysis...
Source: Platelets - April 15, 2021 Category: Hematology Authors: Cole R Clifford Richard G Jung Benjamin Hibbert Aun Yeong Chong Marie Lordkipanidz é Jean-Francois Tanguay Derek Y F So Source Type: research

Not-high before-treatment platelet reactivity in patients with STEMI: prevalence, clinical characteristics, response to therapy and outcomes
Platelets. 2021 Apr 15:1-8. doi: 10.1080/09537104.2021.1915973. Online ahead of print.ABSTRACTPlatelet reactivity (PR) has been indicated as a pathophysiological key element for ST-Elevation Myocardial Infarction (STEMI) development. Patients with not-high before-treatment platelet reactivity (NHPR) have been poorly studied so far. The aim of this study is to investigate the prevalence, clinical characteristics, response to therapy and outcomes of baseline prior to treatment NHPR among patients with STEMI undergoing primary PCI.We analyzed the data from 358 STEMI patients with assessment of PR by VerifyNow before P2Y12 inh...
Source: Platelets - April 15, 2021 Category: Hematology Authors: Mario E Canonico Giuseppe D Sanna Roberta Siciliano Simona Guarino Benedetta Bellandi Fernando Scudiero Pier Sergio Saba Giovanni Esposito Dimitrios Alexopoulos Guido Parodi Source Type: research

Effects of electret coating technology on coronary stent thrombogenicity
Platelets. 2021 Apr 15:1-8. doi: 10.1080/09537104.2021.1912313. Online ahead of print.ABSTRACTStent thrombosis (ST) is a catastrophic event and efforts to reduce its incidence by altering blood-stent interactions are longstanding. A new electret coating technology that produces long-lasting negative charge on stent surface could make them intrinsically resistant to thrombosis. We assessed the thrombogenicity of stents using an annular perfusion model with confocal microscopy, and determined the efficacy of electret coating technology to confer thrombo-resistant properties to standard stents. Using an annular perfusion cham...
Source: Platelets - April 15, 2021 Category: Hematology Authors: M Urooj Zafar Jose Javier Bravo-Cordero Sergi Torramade-Moix Gines Escolar Didac Jerez-Dolz Eli I Lev Juan Jose Badimon Source Type: research

Post-cardiac surgery thrombotic thrombocytopenic purpura: presence of anti-ADAMTS13 autoantibodies at preoperative baseline
Platelets. 2021 Apr 14:1-5. doi: 10.1080/09537104.2021.1912314. Online ahead of print.ABSTRACTThrombotic thrombocytopenic purpura (TTP) rarely complicates acute inflammatory conditions such as surgery, including post-cardiac surgery. Review of 32 previously-reported cases of post-cardiac surgery TTP indicates that this disorder often occurs as early as 2-3 days following surgery, which seems too soon to implicate new formation of anti-ADAMTS13 autoantibodies as a consequence of surgery itself. We diagnosed post-cardiac surgery TTP in a 60-year-old female that began approximately 3 days post-coronary artery bypass surgery i...
Source: Platelets - April 14, 2021 Category: Hematology Authors: Bryan Tordon Theodore E Warkentin Jane C Moore Donald M Arnold Source Type: research

Intravenous abciximab as a rescue therapy for immediate reocclusion after successful mechanical thrombectomy in acute ischemic stroke patients
Platelets. 2021 Apr 11:1-6. doi: 10.1080/09537104.2021.1894326. Online ahead of print.ABSTRACTBackground - Immediate reocclusion after mechanical thrombectomy (MT) for acute ischemic stroke (AIS) is a rare but devastating condition associated with poor functional outcome.Objective - The aim of this study was to gain insights into the mechanisms underlying immediate reocclusion, and to evaluate the efficacy and safety of the glycoprotein IIb/IIIa antagonist abciximab, for its treatment.Methods - Clinical data were collected from April 2015 to April 2019 in a monocentric prospective registry of AIS patients treated by MT. Al...
Source: Platelets - April 12, 2021 Category: Hematology Authors: Fran çois Delvoye Stephane Loyau Julien Labreuche Guillaume Taylor Benjamin Maier Michel Piotin Raphael Blanc Simon Escalard Lucas Di Meglio Malek Ben Maacha Hocine Redjem Stanislas Smajda Gabriele Ciccio Sol ène Hébert Candice Sabben Martine Jandrot-P Source Type: research

A novel frameshift < em > GP1BB < /em > mutation causes autosomal dominant macrothrombocytopenia with decreased vWF receptor expression but normal platelet aggregation
Platelets. 2021 Apr 4:1-4. doi: 10.1080/09537104.2021.1909716. Online ahead of print.ABSTRACTGP1bβ is a component of the von Willebrand factor (vWF) receptor complex that is necessary for platelet formation and activation. A novel frameshift variant in GP1BB has been identified in a family with macrothrombocytopenia. The variant leads to a protein that is 101 amino acids longer than wild type with loss of the transmembrane domain. As there is no defect in platelet aggregation, the family are classified as heterozygous carriers of a Bernard-Soulier syndrome-related mutation. The levels of the vWF receptor on platelets ...
Source: Platelets - April 5, 2021 Category: Hematology Authors: Caitlin Dunstan-Harrison Ian M Morison Elizabeth C Ledgerwood Source Type: research

Safety and efficacy of low-dose ticagrelor in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention
Platelets. 2021 Apr 4:1-8. doi: 10.1080/09537104.2021.1909717. Online ahead of print.ABSTRACTIt remains unclear whether low-dose ticagrelor offers better safety and similar efficacy for Asian patients with acute coronary syndromes (ACS). We aimed to compare the safety and effectiveness of low-dose ticagrelor vs standard-dose ticagrelor in Chinese patients with ACS undergoing percutaneous coronary intervention (PCI). In this observational cohort study, a total of 2110 ACS patients who were event-free at 3 months after the index PCI were divided into standard-dose ticagrelor (90 mg twice daily) (n = 1830) or low-dose ticagre...
Source: Platelets - April 5, 2021 Category: Hematology Authors: Yue Wang Beibei Liu Leilei Chen Yue Wang Zhiqiang Wang Xiaojiang Zhang Min Suo Gary S Mintz Xiaofan Wu Source Type: research

Aquaporins in platelet function
Platelets. 2021 Apr 4:1-7. doi: 10.1080/09537104.2021.1904133. Online ahead of print.ABSTRACTStructurally, aquaporins (AQPs) are small channel proteins with monomers of ~ 30 kDa that are assembled as tetramers to form pores on cell membranes. Aquaporins mediate the conduction of water but at times also small solutes including glycerol across cell membranes and along osmotic gradients. Thirteen isoforms of AQPs have been reported in mammalian cells, and several of these are likely expressed in platelets. Osmotic swelling mediated by AQP1 sustains the calcium entry required for platelet phosphatidylserine exposure and microv...
Source: Platelets - April 5, 2021 Category: Hematology Authors: Ejaife O Agbani Alastair W Poole Source Type: research

Mind the gap: connexins and pannexins in platelet function
Platelets. 2021 Apr 5:1-7. doi: 10.1080/09537104.2021.1902971. Online ahead of print.ABSTRACTConnexins are a family of gap junction forming proteins widely expressed by mammalian cells. They assemble into hexameric hemichannels, which can either function independently or dock with opposing hemichannels on apposite cells, forming a gap junction. Pannexins are structurally related to the connexins but extensive glycosylation of these channels prevents docking to form gap junctions and they function as membrane channels. Platelets express pannexin-1 and several connexin family members (Cx37, Cx40 and Cx62). These channels are...
Source: Platelets - April 5, 2021 Category: Hematology Authors: Kirk A Taylor Gemma Little Jonathan M Gibbins Source Type: research

Response to P. Harrison et al : Characteristics of L-PRP preparations for treating Achilles tendon rupture within the PATH-2 study
Platelets. 2021 Apr 4:1-2. doi: 10.1080/09537104.2021.1902968. Online ahead of print.NO ABSTRACTPMID:33818256 | DOI:10.1080/09537104.2021.1902968 (Source: Platelets)
Source: Platelets - April 5, 2021 Category: Hematology Authors: Cecilia Bec Pauline Francois Axelle Rousset Jeremy Magalon Source Type: research

The structure of CLEC-2: mechanisms of dimerization and higher-order clustering
Platelets. 2021 Apr 5:1-11. doi: 10.1080/09537104.2021.1906407. Online ahead of print.ABSTRACTThe platelet C-type lectin-like receptor CLEC-2 drives inflammation-driven venous thrombosis in mouse models of thrombo-inflammatory disease with a minimal effect on hemostasis identifying it as a target for a new class of antiplatelet agent. Here, we discuss how the protein structure and dynamic arrangement of CLEC-2 on the platelet membrane helps the receptor, which has a single YxxL motif (known as a hemITAM), to trigger intracellular signaling. CLEC-2 exists as a monomer and homo-dimer within resting platelets and forms higher...
Source: Platelets - April 5, 2021 Category: Hematology Authors: Eleyna M Martin Malou Zuidscherwoude Luis A Mor án Ying Di Angel Garc ía Steve P Watson Source Type: research

A novel frameshift < em > GP1BB < /em > mutation causes autosomal dominant macrothrombocytopenia with decreased vWF receptor expression but normal platelet aggregation
Platelets. 2021 Apr 4:1-4. doi: 10.1080/09537104.2021.1909716. Online ahead of print.ABSTRACTGP1bβ is a component of the von Willebrand factor (vWF) receptor complex that is necessary for platelet formation and activation. A novel frameshift variant in GP1BB has been identified in a family with macrothrombocytopenia. The variant leads to a protein that is 101 amino acids longer than wild type with loss of the transmembrane domain. As there is no defect in platelet aggregation, the family are classified as heterozygous carriers of a Bernard-Soulier syndrome-related mutation. The levels of the vWF receptor on platelets ...
Source: Platelets - April 5, 2021 Category: Hematology Authors: Caitlin Dunstan-Harrison Ian M Morison Elizabeth C Ledgerwood Source Type: research

Safety and efficacy of low-dose ticagrelor in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention
Platelets. 2021 Apr 4:1-8. doi: 10.1080/09537104.2021.1909717. Online ahead of print.ABSTRACTIt remains unclear whether low-dose ticagrelor offers better safety and similar efficacy for Asian patients with acute coronary syndromes (ACS). We aimed to compare the safety and effectiveness of low-dose ticagrelor vs standard-dose ticagrelor in Chinese patients with ACS undergoing percutaneous coronary intervention (PCI). In this observational cohort study, a total of 2110 ACS patients who were event-free at 3 months after the index PCI were divided into standard-dose ticagrelor (90 mg twice daily) (n = 1830) or low-dose ticagre...
Source: Platelets - April 5, 2021 Category: Hematology Authors: Yue Wang Beibei Liu Leilei Chen Yue Wang Zhiqiang Wang Xiaojiang Zhang Min Suo Gary S Mintz Xiaofan Wu Source Type: research

Aquaporins in platelet function
Platelets. 2021 Apr 4:1-7. doi: 10.1080/09537104.2021.1904133. Online ahead of print.ABSTRACTStructurally, aquaporins (AQPs) are small channel proteins with monomers of ~ 30 kDa that are assembled as tetramers to form pores on cell membranes. Aquaporins mediate the conduction of water but at times also small solutes including glycerol across cell membranes and along osmotic gradients. Thirteen isoforms of AQPs have been reported in mammalian cells, and several of these are likely expressed in platelets. Osmotic swelling mediated by AQP1 sustains the calcium entry required for platelet phosphatidylserine exposure and microv...
Source: Platelets - April 5, 2021 Category: Hematology Authors: Ejaife O Agbani Alastair W Poole Source Type: research

Mind the gap: connexins and pannexins in platelet function
Platelets. 2021 Apr 5:1-7. doi: 10.1080/09537104.2021.1902971. Online ahead of print.ABSTRACTConnexins are a family of gap junction forming proteins widely expressed by mammalian cells. They assemble into hexameric hemichannels, which can either function independently or dock with opposing hemichannels on apposite cells, forming a gap junction. Pannexins are structurally related to the connexins but extensive glycosylation of these channels prevents docking to form gap junctions and they function as membrane channels. Platelets express pannexin-1 and several connexin family members (Cx37, Cx40 and Cx62). These channels are...
Source: Platelets - April 5, 2021 Category: Hematology Authors: Kirk A Taylor Gemma Little Jonathan M Gibbins Source Type: research

Response to P. Harrison et al : Characteristics of L-PRP preparations for treating Achilles tendon rupture within the PATH-2 study
Platelets. 2021 Apr 4:1-2. doi: 10.1080/09537104.2021.1902968. Online ahead of print.NO ABSTRACTPMID:33818256 | DOI:10.1080/09537104.2021.1902968 (Source: Platelets)
Source: Platelets - April 5, 2021 Category: Hematology Authors: Cecilia Bec Pauline Francois Axelle Rousset Jeremy Magalon Source Type: research

The structure of CLEC-2: mechanisms of dimerization and higher-order clustering
Platelets. 2021 Apr 5:1-11. doi: 10.1080/09537104.2021.1906407. Online ahead of print.ABSTRACTThe platelet C-type lectin-like receptor CLEC-2 drives inflammation-driven venous thrombosis in mouse models of thrombo-inflammatory disease with a minimal effect on hemostasis identifying it as a target for a new class of antiplatelet agent. Here, we discuss how the protein structure and dynamic arrangement of CLEC-2 on the platelet membrane helps the receptor, which has a single YxxL motif (known as a hemITAM), to trigger intracellular signaling. CLEC-2 exists as a monomer and homo-dimer within resting platelets and forms higher...
Source: Platelets - April 5, 2021 Category: Hematology Authors: Eleyna M Martin Malou Zuidscherwoude Luis A Mor án Ying Di Angel Garc ía Steve P Watson Source Type: research

A novel frameshift < em > GP1BB < /em > mutation causes autosomal dominant macrothrombocytopenia with decreased vWF receptor expression but normal platelet aggregation
Platelets. 2021 Apr 4:1-4. doi: 10.1080/09537104.2021.1909716. Online ahead of print.ABSTRACTGP1bβ is a component of the von Willebrand factor (vWF) receptor complex that is necessary for platelet formation and activation. A novel frameshift variant in GP1BB has been identified in a family with macrothrombocytopenia. The variant leads to a protein that is 101 amino acids longer than wild type with loss of the transmembrane domain. As there is no defect in platelet aggregation, the family are classified as heterozygous carriers of a Bernard-Soulier syndrome-related mutation. The levels of the vWF receptor on platelets ...
Source: Platelets - April 5, 2021 Category: Hematology Authors: Caitlin Dunstan-Harrison Ian M Morison Elizabeth C Ledgerwood Source Type: research

Safety and efficacy of low-dose ticagrelor in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention
Platelets. 2021 Apr 4:1-8. doi: 10.1080/09537104.2021.1909717. Online ahead of print.ABSTRACTIt remains unclear whether low-dose ticagrelor offers better safety and similar efficacy for Asian patients with acute coronary syndromes (ACS). We aimed to compare the safety and effectiveness of low-dose ticagrelor vs standard-dose ticagrelor in Chinese patients with ACS undergoing percutaneous coronary intervention (PCI). In this observational cohort study, a total of 2110 ACS patients who were event-free at 3 months after the index PCI were divided into standard-dose ticagrelor (90 mg twice daily) (n = 1830) or low-dose ticagre...
Source: Platelets - April 5, 2021 Category: Hematology Authors: Yue Wang Beibei Liu Leilei Chen Yue Wang Zhiqiang Wang Xiaojiang Zhang Min Suo Gary S Mintz Xiaofan Wu Source Type: research

Aquaporins in platelet function
Platelets. 2021 Apr 4:1-7. doi: 10.1080/09537104.2021.1904133. Online ahead of print.ABSTRACTStructurally, aquaporins (AQPs) are small channel proteins with monomers of ~ 30 kDa that are assembled as tetramers to form pores on cell membranes. Aquaporins mediate the conduction of water but at times also small solutes including glycerol across cell membranes and along osmotic gradients. Thirteen isoforms of AQPs have been reported in mammalian cells, and several of these are likely expressed in platelets. Osmotic swelling mediated by AQP1 sustains the calcium entry required for platelet phosphatidylserine exposure and microv...
Source: Platelets - April 5, 2021 Category: Hematology Authors: Ejaife O Agbani Alastair W Poole Source Type: research

Mind the gap: connexins and pannexins in platelet function
Platelets. 2021 Apr 5:1-7. doi: 10.1080/09537104.2021.1902971. Online ahead of print.ABSTRACTConnexins are a family of gap junction forming proteins widely expressed by mammalian cells. They assemble into hexameric hemichannels, which can either function independently or dock with opposing hemichannels on apposite cells, forming a gap junction. Pannexins are structurally related to the connexins but extensive glycosylation of these channels prevents docking to form gap junctions and they function as membrane channels. Platelets express pannexin-1 and several connexin family members (Cx37, Cx40 and Cx62). These channels are...
Source: Platelets - April 5, 2021 Category: Hematology Authors: Kirk A Taylor Gemma Little Jonathan M Gibbins Source Type: research

Response to P. Harrison et al : Characteristics of L-PRP preparations for treating Achilles tendon rupture within the PATH-2 study
Platelets. 2021 Apr 4:1-2. doi: 10.1080/09537104.2021.1902968. Online ahead of print.NO ABSTRACTPMID:33818256 | DOI:10.1080/09537104.2021.1902968 (Source: Platelets)
Source: Platelets - April 5, 2021 Category: Hematology Authors: Cecilia Bec Pauline Francois Axelle Rousset Jeremy Magalon Source Type: research